Showing results (311-320 of 339) with videos related to

Sort By:
Pageof 34
The Lancet. Oncology|November 17, 2018
Measurable residual disease-guided treatment with azacitidine to prevent haematological relapse in patients with myelodysplastic syndrome and acute myeloid leukaemia (RELAZA2): an open-label, multicentre, phase 2 trialUwe Platzbecker, Jan Moritz Middeke, Katja Sockel, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 7, 2022
Comprehensive Analysis of R-Spondin Fusions and RNF43 Mutations Implicate Novel Therapeutic Options in Colorectal CancerAndreas Seeber, Francesca Battaglin, Kai Zimmer, et al.
Blood|May 22, 2020
A fully human anti-BMP6 antibody reduces the need for erythropoietin in rodent models of the anemia of chronic diseaseVerena Petzer, Piotr Tymoszuk, Malte Asshoff, et al.
NPJ Precision Oncology|July 3, 2023
PBRM1 mutations might render a subtype of biliary tract cancers sensitive to drugs targeting the DNA damage repair systemKai Zimmer, Florian Kocher, Gerold Untergasser, et al.
Blood|September 13, 2019
JAK2-mutant hematopoietic cells display metabolic alterations that can be targeted to treat myeloproliferative neoplasmsTata Nageswara Rao, Nils Hansen, Julian Hilfiker, et al.
Blood|September 4, 2025
Acalabrutinib treatment for older (≥80 years old) and/or frail patients with CLL: primary end point analysis of the CLL-Frail trialFlorian Simon, Rudy Ligtvoet, Jan-Paul Bohn, et al.
Cell Metabolism|April 9, 2020
Single-Cell RNA Sequencing Maps Endothelial Metabolic Plasticity in Pathological AngiogenesisKaterina Rohlenova, Jermaine Goveia, Melissa García-Caballero, et al.
Blood|December 8, 2025
Azacitidine to treat measurable residual disease in patients with MDS/AML: final long-term results of the RELAZA2 trialAnne Sophie Platzbecker, Julia Annabell Georgi, Jan Moritz Middeke, et al.
Blood|December 20, 2018
Midostaurin added to chemotherapy and continued single-agent maintenance therapy in acute myeloid leukemia with FLT3-ITDRichard F Schlenk, Daniela Weber, Walter Fiedler, et al.
Blood Advances|December 11, 2024
Safety and Efficacy of Glofitamab for Relapsed/Refractory Large B-Cell Lymphoma in a Multinational Real-World StudyEvgenii Shumilov, Rebecca Wurm-Kuczera, Andrea Kerkhoff, et al.
Pageof 34